Compare M&T Bank Corporation (MTB) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
M&T Bank Corporation vs Repligen Corporation Common Stock — how do they compare? M&T Bank Corporation trades at $215.86 (market cap $31.47B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: M&T Bank Corporation is far larger — about 2.8× Repligen Corporation Common Stock's market cap, and M&T Bank Corporation pays a 2.75% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold M&T Bank Corporation for 99 Days and Repligen Corporation Common Stock for 0 Days on average.
| MTB | RGEN | |
|---|---|---|
Market Cap | $31.47B | $11.14B |
Volume | 743,357 | 1,259,263 |
Sector | Financials | Health |
52-Week High | $254.09 | $194.57 |
52-Week Low | $178.63 | $102.87 |
Typical Hold Time | 99 Days | 0 Days |
Enterprise Value | $47.83B | $11.02B |
Dividend Yield | 2.75% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
M&T Bank Corporation (MTB) trades at $216.05, down 1.75% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026), a P/E of 11.54, and net income margin of 30.85%. Recent developments include a new Connecticut branch opening and AI investments to drive loan growth. Cash flow trends show operational strength despite negative net cash flow in 2025.
MTB presents a value opportunity with attractive valuation metrics and dividend stability, though technical weakness and competitive banking pressures pose near-term risks. Analyst consensus targets $258.92 (19.8% upside) with 31% buy ratings, but investors should monitor loan growth execution and interest rate sensitivity.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About M&T Bank Corporation
M&T Bank is one of the largest regional banks in the United States, with branches in New York, Pennsylvania, West Virginia, Virginia, Maryland, Delaware, and New Jersey. The bank was founded to serve manufacturing and trading businesses around the Erie Canal and is primarily focused on commercial real estate and commercial-related lending, with some retail operations also present.
Read more on MTB →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
